Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a growing specialty pharmaceutical company focused on dermatology. Cipher acquires products that fulfill high unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly or through partners. Cipher’s key product, a novel version of the acne medication isotretinoin, is marketed as AbsoricaTM in the U.S. and Epurisâ in Canada. Since the Company was founded in 2000, Cipher has achieved regulatory marketing approval in the U.S. and Canada for all three original products and completed eight marketing partnerships, generating growing revenue streams and shareholder value. Cipher is building its dermatology franchise through product licensing and acquisitions.

For more information, please visit www.cipherpharma.com.

Locations:
Mississauga, Ontario | http://www.cipherpharma.com
Industries:
Healthcare Facility|Medical/ Pharmaceuticals
Contact Information:
Craig Armitage
LodeRock Advisors Inc. 
Tel: 416-347-8954
craig.armitage@loderockadvisors.com

Latest

May 10, 2019, 07:00 ET Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

Revenue increased by 12% to $5.1 million OAKVILLE, ON, May 10, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for...


May 01, 2019, 07:30 ET Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

OAKVILLE, ON, May 1, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10,...


Mar 26, 2019, 07:00 ET Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

OAKVILLE, ON, March 26, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of...


Mar 20, 2019, 07:00 ET Cipher Pharmaceuticals Announces Change to Management Team

OAKVILLE, ON, March 20, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has...


Mar 19, 2019, 07:00 ET Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Canadian product revenue increased 30% to $6.9 million for the year Completed six (6) strategic business transactions enhancing long-term value OAKVILLE, ON, March 19, 2019 /CNW/ - Cipher...


Mar 15, 2019, 17:05 ET Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

OAKVILLE, ON, March 15, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2018 financial results conference call on Tuesday, March...


Dec 18, 2018, 07:00 ET Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

MISSISSAUGA, ON, Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of...


Dec 17, 2018, 07:00 ET Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

MISSISSAUGA, ON, Dec. 17, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation...


Dec 05, 2018, 11:00 ET Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

MISSISSAUGA, ON, Dec. 5, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at...


Dec 04, 2018, 07:00 ET Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations

MISSISSAUGA, ON, Dec. 4, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined...


Nov 07, 2018, 07:00 ET Cipher Pharmaceuticals Reports Q3 2018 Results

Canadian product revenue increased 27% MISSISSAUGA, ON, Nov. 7, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for...


Oct 24, 2018, 17:05 ET Notice of Cipher Pharmaceuticals Q3 2018 Conference Call

MISSISSAUGA, ON, Oct. 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2018 financial results conference call on Wednesday,...


Oct 24, 2018, 07:00 ET Cipher Pharmaceuticals Announces Canadian Launch of Brinavess® (vernakalant hydrochloride)

MISSISSAUGA, ON, Oct. 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of Brinavess® (vernakalant hydrochloride) for the rapid conversion of recent onset...


Sep 18, 2018, 07:00 ET Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis

Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market MISSISSAUGA,ON, Sept. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has...


Sep 10, 2018, 16:00 ET Cipher Pharmaceuticals Receives Health Canada Approval of Xydalba™ (dalbavancin hydrochloride)

MISSISSAUGA, ON, Sept. 10, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it received Health Canada approval of Xydalba™ (dalbavancin hydrochloride), the first and only one-dose...


Aug 10, 2018, 07:00 ET Cipher Pharmaceuticals Reports Q2 2018 Results

Canadian product revenue increased 33% MISSISSAUGA, ON, Aug. 10, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results...


Jul 30, 2018, 07:00 ET Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica®

Agreement expanded to include a portfolio of novel isotretinoin products New portfolio royalty extends through December 2024 MISSISSAUGA, ON, July 30, 2018 /CNW/ - Cipher Pharmaceuticals Inc....


Jul 23, 2018, 14:00 ET Notice of Cipher Pharmaceuticals Q2 2018 Conference Call

MISSISSAUGA, ON, July 23, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2018 financial results conference call on Friday, August ...


Jun 06, 2018, 07:00 ET Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs

MISSISSAUGA, ON, June 6, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry medical executive, Dr. Diane Gajewczyk, has...


May 16, 2018, 08:00 ET Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

MISSISSAUGA, ON, May 16, 2018 /CNW/ - Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp....


May 15, 2018, 09:00 ET Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma

MISSISSAUGA, ON, May 15, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced strategic acquisition of the Canadian business portfolio of...


May 11, 2018, 12:00 ET Cipher Pharmaceuticals Reports Voting Results for the Election of Directors

MISSISSAUGA, ON, May 11, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for ...


May 01, 2018, 07:00 ET Notice of Cipher Pharmaceuticals Q1 2018 Conference Call & Annual Meeting

MISSISSAUGA, ON, May 1, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2018 financial results conference call and Annual and...


Apr 26, 2018, 07:00 ET Cipher Pharmaceuticals Proposes Adding Dr. Laurence Terrisse-Rulleau To Board of Directors

MISSISSAUGA, ON, April 26, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being...


Apr 24, 2018, 07:00 ET Cipher Pharmaceuticals to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, ON, April 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Robert Tessarolo, President and Chief Executive Officer, will present at ...